| Low disease activity—irrespective of serologic status at baseline—associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus … A Fanouriakis, C Adamichou, S Koutsoviti, S Panopoulos, C Staveri, ... Seminars in arthritis and rheumatism 48 (3), 467-474, 2018 | 75 | 2018 |
| What's new in the treatment of systemic lupus erythematosus SN Liossis, C Staveri Frontiers in Medicine 8, 655100, 2021 | 50 | 2021 |
| New onset of lupus nephritis in two patients with SLE shortly after initiation of treatment with belimumab C Staveri, D Karokis, SNC Liossis Seminars in Arthritis and Rheumatism 46 (6), 788-790, 2017 | 34 | 2017 |
| B cell-based treatments in SLE: past experience and current directions SNC Liossis, C Staveri Current rheumatology reports 19, 1-10, 2017 | 19 | 2017 |
| The role of b cells in scleroderma lung disease pathogenesis SNC Liossis, C Staveri Frontiers in Medicine 9, 936182, 2022 | 8 | 2022 |
| Rituximab for SLE refractory to conventional treatment: results of a cohort evaluating efficacy and long-term outcome C Staveri, SN Liossis CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 34 (4), S5-S5, 2016 | 3 | 2016 |
| Treatment evolution of Systemic Lupus Erythematosus C Staveri Achaiki Iatriki, 211, 2022 | | 2022 |
| FRI0310 Achievement of low disease activity in lupus patients treated with belimumab is independent of serologic status at baseline: a real-life observational study A Fanouriakis, C Adamichou, S Koutsoviti, S Panopoulos, C Staveri, ... Annals of the Rheumatic Diseases 77 (Suppl 2), 692-692, 2018 | | 2018 |
| Lupus nephritis: To biopsy or not to biopsy SNC Liossis, C Staveri | | |
